Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
39 chronic schizophrenic out-patients were given either fluphenazine decanoate or enanthate for a 1-year double-blind trial. Doses of 25 mg were given for the first 6 months and 37.5 mg for the last 6 months. For both agents the intervals between treatments lengthened significantly over the course of the trial. Fluphenazine decanoate showed a non-significant trend for a longer duration of action coupled with a significantly lower incidence of extrapyramidal side effects.
D000328:Adult; D000553:Ambulatory Care; D002908:Chronic Disease; D003652:Decanoic Acids; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006537:Heptanoates; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*
D003652:Decanoic Acids; D003692:Delayed-Action Preparations; D006537:Heptanoates; D005476:Fluphenazine